RESEARCH TRIANGLE PARK, NC, Nov. 5, 2020 — Pappas Capital, a leading venture capital firm focused on advancing life sciences, today announced that its portfolio company, VelosBio Inc. (“VelosBio” or the...
After Change Up Top, Syntonix Inks Boehringer Ingelheim Deal Worth Up to $63M
News | 10. 24. 2005
Syntonix Pharmaceuticals
After a management change over the summer, drug formulation and delivery company Syntonix Pharmaceuticals Inc. has kicked off autumn with a collaboration with Boehringer Ingelheim GmbH that could bring in as much as $63 million.
